Personalized medicine and opioid use disorder

doi:10.5498/wjp.v14.i9.1285

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (617)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

478

Sum=500

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=84

Sep 19, 2024 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Psychiatry. Sep 19, 2024; 14(9): 1285-1288
Published online Sep 19, 2024. doi: 10.5498/wjp.v14.i9.1285

Personalized medicine and opioid use disorder

Dilek Kaya-Akyüzlü

Dilek Kaya-Akyüzlü, Institute of Forensic Sciences, Ankara University, Ankara 06590, Türkiye

Author contributions: Kaya-Akyüzlü D designed the overall concept and outline of the manuscript, reviewed the literature, and wrote and edited the manuscript.

Conflict-of-interest statement: The author has no conflicts of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Dilek Kaya-Akyüzlü, PhD, Associate Professor, Institute of Forensic Sciences, Ankara University, Balkiraz Mah. Mamak Cad. No. 27, Dikimevi, Ankara 06590, Türkiye. akyuzludilek@gmail.com

Received: April 27, 2024
Revised: July 30, 2024
Accepted: August 7, 2024
Published online: September 19, 2024
Processing time: 136 Days and 12.7 Hours

Core Tip

Core Tip: Although maintenance treatment with methadone or buprenorphine is effective for treating opioid use disorder, the rate of treatment failure is high among patients, which leads to significant costs to society in terms of healthcare and justice. Thus, it is important to understand the genetic information of patients to increase treatment effectiveness. There has been evidence showing the interaction between genetic variants and the rate of metabolism, the mechanism of action and transport of drugs. Therefore, patient-tailored treatment would be a good approach to facilitate longer periods of abstinence in addicts who are at high risk of treatment failure.